Payment overview · 2025
General Payments
$14,113.50
83 reported records · 22 companies
Healthcare provider profile · identity verified
Bhuvin Mukesh Buddhdev, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PHOENIX, AZ · NPI 1881907681
Verified facts
What the public records show
CMS Open Payments records show Bhuvin Mukesh Buddhdev, MD received $14,113.50 in general payments during 2025 across 83 reported records.
United Therapeutics Corporation accounted for 78.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adempas, Cresemba, Opsumit, Prevymis.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Opsumit by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Cresemba by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Adempas by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Johnson & Johnson Health Care Systems Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 212 records involving 41 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Opsumit by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Adempas by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PREVYMIS as an associated drug or biological on 2265 records involving 1245 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Prevymis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $11,100.45 | 78.7% | 34 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $1,671.21 | 11.8% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $271.50 | 1.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $200.00 | 1.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $164.74 | 1.2% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $140.41 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $127.30 | 0.9% | 4 | 2025 |
| Johnson & Johnson Health Care Systems Inc. | Unresolved — no canonical attribution shown | $106.76 | 0.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.50 | 0.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.73 | 0.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.13 | 0.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.70 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.57 | 0.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.59 | 0.2% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $21.90 | 0.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.84 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.23 | 0.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.60 | 0.1% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $14.05 | 0.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $13.81 | 0.1% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $13.62 | 0.1% | 1 | 2025 |
| Breas Medical, Inc. | Unresolved — no canonical attribution shown | $9.86 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $9,265.00 | 4 |
| Food and Beverage | $4,036.87 | 71 |
| Travel and Lodging | $811.63 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TYVASO Normalized: tyvaso |
Drug | United Therapeutics Corporation | $7,850.53 | 17 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc., Johnson & Johnson Health Care Systems Inc. | $1,748.98 | 15 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc., Johnson & Johnson Health Care Systems Inc. | $1,131.02 | 12 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $184.74 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $164.74 | 7 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $147.29 | 2 | 2025 |
Source payment records
|
|||||
| Orenitram Normalized: orenitram |
Drug | United Therapeutics Corporation | $128.65 | 1 | 2025 |
Source payment records
|
|||||
| Remodulin Normalized: remodulin |
Drug | United Therapeutics Corporation | $128.65 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $124.21 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $60.28 | 3 | 2025 |
Source payment records
|
|||||
| PREVYMIS Normalized: prevymis |
Drug | Merck Sharp & Dohme LLC | $54.05 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $51.50 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $37.73 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| TREPROSTINIL Normalized: treprostinil |
Drug | Sandoz Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| Vivo 45 LS Normalized: vivo 45 ls |
Device | Breas Medical, Inc. | $9.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Adempas adempas |
2025 | Adempas | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Cresemba cresemba |
2025 | Cresemba | 2024 | 58 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PREVYMIS prevymis |
2025 | Prevymis | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Johnson & Johnson Health Care Systems Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 212 supporting records · 41 recipient NPIs · example record 1173788150 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PREVYMIS open payments reported associated product |
CMS Open Payments — General Payments 2265 supporting records · 1245 recipient NPIs · example record 1237992506 |
Prevymis · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 233 | 95 |
| Montelukast Sodium | Montelukast Sodium | 159 | 57 |
| Azithromycin | Azithromycin | 157 | 57 |
| Itraconazole | Itraconazole | 111 | 33 |
| Omeprazole | Omeprazole | 111 | 48 |
| Valganciclovir Hcl | Valganciclovir Hcl | 103 | 39 |
| Acyclovir | Acyclovir | 95 | 36 |
| Alendronate Sodium | Alendronate Sodium | 78 | 30 |
| Eliquis | Apixaban | 77 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 37 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 75 | 22 |
| Prevymis | Letermovir | 71 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 27 |
| Furosemide | Furosemide | 60 | 33 |
| Cresemba | Isavuconazonium Sulfate | 58 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 24 |
| Tacrolimus | Tacrolimus | 57 | 19 |
| Posaconazole | Posaconazole | 56 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 26 |
| Opsumit | Macitentan | 46 | suppressed |
| Atovaquone | Atovaquone | 45 | 12 |
| Pirfenidone | Pirfenidone | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 17 |
| Gabapentin | Gabapentin | 37 | 15 |
| Ofev | Nintedanib Esylate | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 14 |
| Amoxicillin | Amoxicillin | 29 | 18 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 27 | suppressed |
| Tadalafil | Tadalafil | 24 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Tyvaso Dpi | Treprostinil | 22 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 17 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 15 | suppressed |
| Adempas | Riociguat | 14 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,113.50 · 83 records | United Therapeutics Corporation | AIRSUPRA, AVYCAZ, Adempas, Arikayce, Brinsupri, Cresemba, DUPIXENT, EMBLAVEO, FASENRA, Fetroja, GLASSIA, JASCAYD, KEYTRUDA, NUCALA, OPSUMIT, OPSYNVI, Ohtuvayre, Orenitram, PEMGARDA, PREVYMIS, PURIFIED CORTROPHIN GEL, Remodulin, TREPROSTINIL, TYVASO, UPTRAVI, Vest Therapy Und, Vivo 45 LS, ZENPEP, ZERBAXA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adempas play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error